RecruitingProstate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Eligible age

18+ yrs

Accepts

Men

Locations

8 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).

Sponsor: Acerand Therapeutics (Hong Kong) Limited

You may qualify if…

✓ Provide written informed consent
✓ Metastatic Castration-resistant Prostate Cancer with ongoing androgen - deprivation therapy (ADT) or have bilateral orchiectomy
✓ Difficult to treat or intolerant to standard treatment (post at least 1 line of NHA and taxane-based chemo in mHSPC or mCRPC), suitable for investigational treatment;
✓ Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
✓ Has a life expectancy of at least 6 months
✓ Adequate organ function and bone marrow function

You may not qualify if…

✕ Receiving any anti-cancer drugs or other treatment, major surgery, extensive radiation therapy, or local radiation therapy within protocol-defined wash-out period;
✕ Concomitant use of medications or herbal supplements known to be moderate to strong CYP3A4 inhibitors/inducers, or P-gp inhibitors, known to prolong the QT interval.
✕ Any previous treatment-related toxicities have not recovered.
✕ Spinal cord compression or known brain metastases or leptomeningeal carcinomatosis.
✕ Severe cardiovascular disorders.
✕ Known gastrointestinal (GI) disorder or GI procedure
✕ History of gastric and duodenal perforation.
✕ History of pituitary dysfunction.

Where it's recruiting

La Jolla

Tampa

Baltimore

Boston

Minneapolis

Omaha

Myrtle Beach

Seattle

Source: ClinicalTrials.gov · NCT06801236 · last updated 2026-09-25